Cellularized Skin Substitute Bioengineering for Regenerative Medicine: Cell Sources, Culture Strategies, and Transition Toward Defined, Xeno‐Free Culture Systems
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.71630 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Gilles Lemaître und 7 weiteren Autor:innen. Beteiligte Einrichtung: CEA, Laboratoire de Régénération et Radiopathologies Cutanées (LR2C), Evry, France. Hauptthemen laut MEDLINE: Regenerative Medicine, Skin, Artificial, Tissue Engineering, Cell Culture Techniques. Die Arbeit nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Priority Research Program and Equipment, Fondation pour la Recherche Médicale.
Abstract (Originalsprache)
The skin provides a model for regenerative medicine, prompting the design of cultured reconstructed tissue substitutes. Translational research and bioengineering have indeed given rise to clinical applications such as the grafting of cultured skin substitutes in severe burn patients, more than four decades ago, and more recently the correction of a genodermatosis by a cell and gene therapy approach. In addition, therapeutic uses of bioengineered skin substitutes are considered for chronic wounds and ulcers, which affect much larger patient populations. This history has given rise to multiple innovations involving original concepts, combined with new methodological and technical approaches. The variables relate to the cell sources used, which may include cells from neonatal or adult skin, autologous or allogeneic, or skin cells obtained by directed differentiation of pluripotent stem cells. They also concern methods and culture protocols used for cell expansion phase in two‐dimensional (2D) culture, then the production phase of 3D skin substitutes, a major current challenge being the elimination of constituents not chemically defined and/or of animal origin. By outlining the main technological options, this review aims to guide the design of next‐generation skin substitutes that will reconcile biological performance, regulatory expectations and realistic clinical implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CEA, Laboratoire de Régénération et Radiopathologies Cutanées (LR2C), Evry, France.
- CEA, Institut de Biologie François Jacob (IBFJ), Département de Radiobiologie Cellulaire et Moléculaire (DRCM), France.
- INSERM UMR Stabilité Génétique Cellules Souches et Radiations, France.
- Université Evry Paris-Saclay, France.
- Centre de Transfusion Sanguine des Armées, Hôpital Percy, Clamart, France.
- Inserm, Villejuif, France.
ORCID-Profile: Gilles Lemaître, Marina Trouillas, Tatiana Vinasco-Sandoval, Cécile Giordano, Alexandre G Lellouch, Walid Rachidi, Nicolas O Fortunel
Förderung
- Priority Research Program and Equipment
- Fondation pour la Recherche Médicale
Zitieren
APA
Lemaître, G., Trouillas, M., Vinasco-Sandoval, T., Giordano, C., Lellouch, A. G., Rachidi, W., Lataillade, J. J., & Fortunel, N. O. (2026). Cellularized Skin Substitute Bioengineering for Regenerative Medicine: Cell Sources, Culture Strategies, and Transition Toward Defined, Xeno‐Free Culture Systems. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71630
Vancouver
Lemaître G, Trouillas M, Vinasco-Sandoval T, Giordano C, Lellouch AG, Rachidi W, et al. Cellularized Skin Substitute Bioengineering for Regenerative Medicine: Cell Sources, Culture Strategies, and Transition Toward Defined, Xeno‐Free Culture Systems. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71630
BibTeX
@article{Lematre2026,
author = {Lemaître, Gilles and Trouillas, Marina and Vinasco-Sandoval, Tatiana and Giordano, Cécile and Lellouch, Alexandre G and Rachidi, Walid and Lataillade, Jean-Jacques and Fortunel, Nicolas O},
title = {Cellularized Skin Substitute Bioengineering for Regenerative Medicine: Cell Sources, Culture Strategies, and Transition Toward Defined, Xeno‐Free Culture Systems},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71630}
}
EUVIMED